United Therapeutics (UTHR) Total Debt (2010 - 2025)

United Therapeutics has disclosed Total Debt across 14 years of filings, most recently posting $200.0 million for Q1 2025.

• Total Debt for Q1 2025 came in at $200.0 million, down 66.67% year-over-year; the trailing twelve-month figure through Mar 2025 was $200.0 million (down 66.67% YoY), and the FY2024 annual result was $300.0 million, down 57.14% from the prior year.
• Total Debt came in at $200.0 million for Q1 2025 at United Therapeutics, down from $300.0 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $800.0 million in Q1 2021 to a low of $200.0 million in Q1 2025.
• The 5-year median for Total Debt is $800.0 million (2021), against an average of $676.5 million.
• Across the five-year window, Total Debt changed 0.0% in 2021 and sank 66.67% in 2025, its largest moves.
• United Therapeutics' Total Debt stood at $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then declined by 12.5% to $700.0 million in 2023, then sank by 57.14% to $300.0 million in 2024, then plunged by 33.33% to $200.0 million in 2025.
• The last three Total Debt figures came in at $200.0 million (Q1 2025), $300.0 million (Q4 2024), and $400.0 million (Q3 2024), per Business Quant data.